Pregabalin Capsule
Product Images NDC 72162-1546

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1546). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621546)

Pregabalin Capsules 200 mg oral dosage form label, containing 90 capsules. The label shows the NDC 72162-1546-9 and states the active ingredient strength as Pregabalin, USP 200 mg per capsule. The labeler is Bryant Ranch Prepack, with manufacturing by ScieGen Pharmaceuticals, Inc. Storage instructions specify controlled room temperature between 20° to 25° C.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for different Pregabalin doses and placebo. Four lines represent Pregabalin 200 mg, 100 mg, and 25 mg three times a day, and placebo. The x-axis shows percent improvement in pain, while the y-axis indicates percent of patients improved.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. The graph shows two lines representing Pregabalin 100 mg three times a day and placebo, illustrating differences in patient pain improvement over various percentage thresholds.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, with distinct line styles for each group.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percentage of patients improved as a function of percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis is percent of patients improved, and the x-axis is percent improvement in pain. The graph illustrates higher improvement rates for Pregabalin doses compared to placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating varying levels of pain improvement across these groups.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart showing responder rates (%) in two separate studies, Study E1 and Study E3. The chart compares placebo and varying dosages of the drug, with responder rates increasing as dosage increases. Statistical significance versus placebo is noted for higher doses in both studies.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing median percent change in seizure reduction from baseline versus dose (mg/day) in multiple studies labeled E1, E2, and E3 with TID and BID dosing. Data points indicate significant p-values for seizure reduction at various doses compared to placebo, with higher doses associated with greater seizure reduction.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg compared to placebo. The graph plots four curves, illustrating patient response across increasing pain improvement percentages, with vertical lines marking specific improvement thresholds.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing Pregabalin and placebo over 180 days, showing the estimated percentage of subjects without LTR on the vertical axis and days on the horizontal axis. The Pregabalin group demonstrates a higher percentage of subjects without LTR over time compared to placebo, with two lines labeled accordingly: a solid line for Pregabalin and a dashed line for placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved from baseline to week 12 using BOCF analysis for Pregabalin versus Placebo. The x-axis represents percent improvement ranging from 0 to 100, and the y-axis shows percent of subjects improved from 0 to 100%. Pregabalin shows higher improvement rates compared to placebo across most of the scale.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to week 16 BOCF between Pregabalin and Placebo groups. The x-axis represents percent improvement from 0 to 100%, and the y-axis shows the percent of subjects improved from 0 to 100%. Pregabalin consistently shows higher improvement than Placebo across all percentage levels.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula displaying the calculation for creatinine clearance (CLcr) based on age in years, weight in kilograms, and serum creatinine in mg/dL, with an adjustment factor of 0.85 for female patients. This formula is commonly used in clinical contexts to estimate kidney function.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of pregabalin, showing its molecular configuration with labeled functional groups, including an amino group and a carboxyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.